These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35113414)

  • 21. Total and transition zone prostate volume and age: how do they affect the utility of PSA-based diagnostic parameters for early prostate cancer detection?
    Djavan B; Zlotta AR; Remzi M; Ghawidel K; Bursa B; Hruby S; Wolfram R; Schulman CC; Marberger M
    Urology; 1999 Nov; 54(5):846-52. PubMed ID: 10565745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score ≥ 7 prostate cancer from group of biopsy-based Gleason score ≤ 6.
    Wang H; Gu L; Wu Y; Feng D; Duan J; Wang X; Huang Y; Wu S; Chen J; Luo G; Zhang X
    BMC Cancer; 2017 Sep; 17(1):629. PubMed ID: 28874127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnosis of Prostate Cancer in Patients with Prostate-Specific Antigen (PSA) in the Gray Area: Construction of 2 Predictive Models.
    Chen M; Ma T; Li J; Zhang HJ; Li Q; Wang JJ; Sang T; Cao CL; Cui XW
    Med Sci Monit; 2021 Feb; 27():e929913. PubMed ID: 33556045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic Role of Serum Free-to-Total Prostate Specific Antigen (PSA) Ratio in Prostate Cancer with Serum Total Concentration of PSA below 4 ng/mL.
    Chang CC; Lee YC; Tsai HW; Yii SC; Yen TH; Chu FY
    Asian Pac J Cancer Prev; 2015; 16(13):5261-4. PubMed ID: 26225663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter.
    Horninger W; Cheli CD; Babaian RJ; Fritsche HA; Lepor H; Taneja SS; Childs S; Stamey TA; Sokoll LJ; Chan DW; Brawer MK; Partin AW; Bartsch G
    Urology; 2002 Oct; 60(4 Suppl 1):31-5. PubMed ID: 12384160
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Establishment of a scoring system for predicting the positive rate of prostatic biopsy for prostate cancer].
    Chen JG; Chen XF; Gu DH; Lu M; Zheng B; Zhang B; Pan B; Zhu H; Pan XD; Xu B; Qian L
    Zhonghua Nan Ke Xue; 2015 Jan; 21(1):53-6. PubMed ID: 25707141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic approach to prostate cancer using total prostate specific antigen-based parameters together.
    Serdar MA; Oguz O; Olgun A; Seçkin B; Ilgan S; Hasimi A; Salih M; Peker F; Kutluay T
    Ann Clin Lab Sci; 2002; 32(1):22-30. PubMed ID: 11848613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of prostate specific antigen density to predict clinically significant prostate cancer.
    Yusim I; Krenawi M; Mazor E; Novack V; Mabjeesh NJ
    Sci Rep; 2020 Nov; 10(1):20015. PubMed ID: 33203873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PSA density as a better predictor of prostate cancer than percent-free PSA in a repeat biopsy.
    Chen CS; Wang SS; Li JR; Cheng CL; Yang CR; Chen WM; Ou YC; Ho HC; Chiu KY; Yang CK
    J Chin Med Assoc; 2011 Dec; 74(12):552-5. PubMed ID: 22196470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic value of MRI-based PSA density in predicting transperineal sector-guided prostate biopsy outcomes.
    MacAskill F; Lee SM; Eldred-Evans D; Wulaningsih W; Popert R; Wolfe K; Van Hemelrijck M; Rottenberg G; Liyanage SH; Acher P
    Int Urol Nephrol; 2017 Aug; 49(8):1335-1342. PubMed ID: 28477301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.
    Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A
    Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new model consists of intravesical prostatic protrusion, prostate volume and serum prostatic-specific antigen in the evaluation of prostate cancer.
    Xu D; Yu Y; Zhu Y; Huang T; Chen Y; Qi J
    Pathol Oncol Res; 2014 Apr; 20(2):439-43. PubMed ID: 24178678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MRI-Based Prostate-Specific Antigen Density Predicts Gleason Score Upgrade in an Active Surveillance Cohort.
    Washington SL; Baskin AS; Ameli N; Nguyen HG; Westphalen AC; Shinohara K; Carroll PR
    AJR Am J Roentgenol; 2020 Mar; 214(3):574-578. PubMed ID: 31913068
    [No Abstract]   [Full Text] [Related]  

  • 34. Analysis of risk factors for determining the need for prostate biopsy in patients with negative MRI.
    Liang L; Qi F; Cheng Y; Zhang L; Cao D; Cheng G; Hua L
    Sci Rep; 2021 Mar; 11(1):6048. PubMed ID: 33723287
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significance of the prostate central gland and total gland volume ratio in the diagnosis of prostate cancer patients in the prostate specific antigen grey zone.
    Guo ZF; Yang F; Lu XW; Wu JW; He C; Han CH
    J Int Med Res; 2021 Jul; 49(7):3000605211019879. PubMed ID: 34308690
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive value of PSA density in the diagnosis of prostate cancer in lebanese men.
    Msheik A; Mohanna M; Mhanna A; Kanj A; Moussa M; Mohanna A
    Arch Ital Urol Androl; 2022 Mar; 94(1):18-24. PubMed ID: 35352520
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The usefulness of percentage of free prostate specific antigen/prostate specific antigen density in the diagnosis of prostate cancer].
    Han G; Gao JP; Cao XL; Hong BF; Tang J
    Zhonghua Wai Ke Za Zhi; 2006 Mar; 44(6):379-81. PubMed ID: 16638346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strategy for Prostate Cancer Patients with Low Prostate Specific Antigen Level (2.5 to 4.0 ng/mL).
    Chung JH; Yu J; Song W; Kang M; Sung HH; Jeon HG; Jeong BC; Seo SI; Lee HM; Jeon SS
    J Korean Med Sci; 2020 Oct; 35(41):e342. PubMed ID: 33107227
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ON THE ISSUE OF NECESSITY TO PERFORM THE DR-70 IMMUNOASSAY PRIOR TO PROSTATE BIOPSY IN PATIENTS WITH HIGH PROSTATE SPECIFIC ANTIGEN LEVEL AND ITS EFFICACY IN PREDICTING THE BIOPSY RESULTS.
    Ediz C; Akan S; Temel CM; Tavukcu HH; Yilmaz O
    Georgian Med News; 2019 Sep; (294):22-26. PubMed ID: 31687943
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate Health Index outperforms other PSA derivatives in predicting a positive biopsy in men with tPSA <10 ng/mL: Largest prospective cohort in Taiwan.
    Fan YH; Pan PH; Lin TP; Huang TH; Wei TC; Huang IS; Lin CC; Huang EYH; Chung HJ; Huang WJS
    J Chin Med Assoc; 2019 Oct; 82(10):772-777. PubMed ID: 31356566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.